Danaher is a conglomerate of companies that have four basic groups. 
From the website:
“Danaher’s business activities encompass four reporting segments and are comprised of seven strategic platforms: Medical Technologies (Life Sciences & Diagnostics and Dental), Professional Instrumentation (Environmental, Test & Measurement), Industrial Technologies (Motion, Product ID, Focused Niche Businesses) and Tools & Components (Mechanic’s Hand Tools).”
The CEO of Danaher also happens to be a member of the Board of Directors for GlaxoSmithKline. Danaher is headquartered in Washington DC and here’s a link if you want to explore all the companies they presently own, like at VC or PE group it seems.
Beckman Coulter sells DNA sequencing equipment and has various areas 
dedicated to research and development with stem cells, biomarkers, etc. so we definitely want to be sure their data houses are in divine order.
Business Intelligence Software Breakdown At Beckman Coulter – Algorithms gone Rogue and Data House Repair
It was so bad that the board of directors could not validate the company financial reports, a dangerous item if you are traded as a company on the open market and provide false information either on purpose or by accident so obviously they got their act and data together. The Biotech company has also been under the gun with trying to find a new HMO plan for their employees in Orange County, CA last year as even biotech companies are hit with high health insurance increases and perhaps with the buy out that may leave new options on the table. BD
Employers in Orange County Looking for New HMO Contracts as St. Josephs and Some Others Begin Cancelling Agreements with Pacificare (UnitedHeatlhCare) – Employer Capitation Contracts
Danaher agreed to acquire medical-test maker Beckman Coulter for $5.87 billion as the diversified manufacturer looks to gain a stronger foothold in the growing diagnostics industry.
Under the terms of the deal, Danaher will pay $83.50 for each Beckman share, which the companies said represents a premium of about 45% over where the stock was trading Dec. 9, before takeover rumors surfaced.
Danaher said it is covering 25% of the deal with cash on hand, 60% from new and assumed debt and 15% from equity. The company plans to pay down a “sizable” amount of debt this year, Chief Financial Officer Daniel L. Comas said on a conference call.
Deal Profile: Danaher to Buy Beckman Coulter for $5.87 Billion - Deal Journal - WSJ
0 comments :
Post a Comment